Robbins K C
Mol Cell Biochem. 1978 Aug 16;20(3):149-57. doi: 10.1007/BF00243761.
The factors involved in the regulation and control of the human plasma fibrinolytic system at the cellular level are unknown at this time. The physiological regulation of plasmin formation in plasma depends primarily on the nature of the circulating zymogen, plasminogen, the physiological activators formed both in the blood and in the vascular endothelium, and the specific plasmin inhibitors found both in plasma and in certain of the cellular elements of the blood. The biosynthesis of the zymogen must be under genetic control, and the activators are probably released, after thrombus and clot formation, from components involved in the surface-mediated initiation of the coagulation system, and from the vascular endothelium. Activation of plasminogen can occur both in the fluid phase surrounding the thrombus and probably at thrombus surfaces, involving both the fibrin clot and the platelet membrane. The plasmin inhibitors act to control the system in order to prevent proteolytic degradation of important physiologic trace proteins of the coagulation, complement and kallikrein-kinin systems by the enzyme.
目前,细胞水平上参与人体血浆纤维蛋白溶解系统调节与控制的因素尚不清楚。血浆中纤溶酶形成的生理调节主要取决于循环中的酶原(纤溶酶原)的性质、在血液和血管内皮中形成的生理激活剂,以及在血浆和血液某些细胞成分中发现的特异性纤溶酶抑制剂。酶原的生物合成必定受遗传控制,激活剂可能在血栓和凝块形成后,从参与凝血系统表面介导起始过程的成分以及血管内皮中释放出来。纤溶酶原的激活可发生在血栓周围的液相中,也可能发生在血栓表面,涉及纤维蛋白凝块和血小板膜。纤溶酶抑制剂发挥作用来控制系统,以防止该酶对凝血、补体和激肽释放酶 - 激肽系统中重要的生理微量蛋白进行蛋白水解降解。